Cocaine Abuse: Clinical Trials

15 trials for Cocaine Abuse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 1 terminated. 15 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 115Completed 14, Terminated 1

Follow Cocaine Abuse: new trials by email Literature Review of Cocaine Abuse trials Research Report on Cocaine Abuse

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
Clavulanic acid, Intravenous cocaine, Placebo - Cocaine Dependence, Cocaine Addiction
Phase 1CompletedTemple University102016-10-242023-11-03
Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin
Lorcaserin, Placebo, Cocaine Infusion - Cocaine Abuse
Phase 1CompletedNational Institute on Drug Abuse (NIDA)202015-05-012017-01-11
Pramipexole as a Treatment for Cocaine Dependence
Pramipexole, Placebo - Cocaine Addiction, Cocaine Abuse
Phase 1CompletedBaylor College of Medicine102011-10-012014-07-22
ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
ALKS 33-BUP, ALKS 33, Placebo - Cocaine Abuse
Phase 1CompletedAlkermes, Inc.332011-08-012012-03-09
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence
Placebo, Cabergoline - Cocaine Dependence, Cocaine Abuse
Phase 1CompletedBaylor College of Medicine112011-07-012012-07-27
Modafinil - Escitalopram Study for Cocaine Dependence
Modafinil and Escitalopram, Placebo, Modafinil - Cocaine Dependence, Cocaine Abuse
Phase 1CompletedBaylor College of Medicine682010-08-012012-05-18
Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)
L-dopa / carbidopa / entacapone (LCE) - Cocaine Abuse
Phase 1CompletedNew York State Psychiatric Institute152010-08-012018-05-21
The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine
Placebo, Doxazosin - Cocaine Addiction, Cocaine Abuse
Phase 1CompletedBaylor College of Medicine132010-01-012012-07-27
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Placebo, Rivastigmine 3 mg, Huperzine A 0.4 mg - Cocaine Dependence, Cocaine Addiction
Phase 1CompletedBaylor College of Medicine722009-01-012015-01-27
Computer-Based Training in Cognitive Behavior Therapy
Treatment as usual (TAU), CBT for CBT - Cocaine Abuse
Phase 1CompletedYale University1002007-11-012013-01-29
Effect of Clonidine on Responses to Imagery Scripts
Clonidine, Placebo - Cocaine Abuse, Heroin Abuse
Phase 1CompletedNational Institute on Drug Abuse (NIDA)922005-06-142018-04-05
CBT With Disulfiram and Contingency Management
disulfiram, Placebo, Placebo plus Contingency Management - Cocaine Abuse
Phase 1CompletedYale University1812005-04-012014-12-03
Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals
GBR 12909 - Cocaine Abuse, Cocaine-Related Disorders
Phase 1TerminatedNational Institute on Drug Abuse (NIDA)32004-12-012017-01-12
Long Term Maintenance of Drug Abstinence
Contingency Management - Cocaine Dependence, Cocaine Abuse
Phase 1CompletedTreatment Research Institute1662004-09-012023-03-28
Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse
Methadone, Contingency Management - Opioid Dependence, Cocaine Abuse
Phase 1CompletedNational Institute on Drug Abuse (NIDA)2001999-06-012017-01-12

Narrower conditions

Cocaine-Related Disorders (15)  ·  Substance-Related Disorders (6)  ·  Heroin Dependence (1)  ·  Opioid-Related Disorders (1)  ·  Recurrence (1)

Broader conditions

Chemically-Induced Disorders (15)  ·  Mental Disorders (15)  ·  Substance-Related Disorders (9)  ·  Narcotic-Related Disorders (2)  ·  Disease Attributes (1)  ·  Opioid-Related Disorders (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Sugars (5)  ·  Buprenorphine (1)  ·  Cabergoline (1)  ·  Carbidopa (1)  ·  Clavulanic Acid (1)  ·  Clonidine (1)  ·  Disulfiram (1)  ·  Doxazosin (1)  ·  Escitalopram (1)  ·  Levodopa (1)  ·  Methadone (1)  ·  Modafinil (1)  ·  Pramipexole (1)  ·  Rivastigmine (1)  ·  Therapeutics (1)

Sponsors

Baylor College of Medicine (5)  ·  National Institute on Drug Abuse (NIDA) (4)  ·  Yale University (2)  ·  Alkermes, Inc. (1)  ·  New York State Psychiatric Institute (1)  ·  Temple University (1)  ·  Treatment Research Institute (1)

Countries

United States (14)

Top investigators

Adam Bisaga, M.D. (1)  ·  Bernard L. Silverman, MD (1)  ·  Debra Kelsh, Ph.D. (1)  ·  John Grabowski, PhD (1)  ·  Kathleen Carroll, PhD (1)  ·  Kathleen M. Carroll, PhD (1)  ·  Kenzie Preston, Ph.D. (1)  ·  Kenzie Preston, PhD (1)  ·  Kimberly C Kirby, Ph.D. (1)  ·  Kyle M. Kampman, M.D. (1)  ·  M. I Walters, M.D. (1)  ·  Mary F. Morrison, M.D., M.S. (1)  ·  Richard De La Garza, II, PhD (1)  ·  Richard De La Garza, Ph.D. (1)  ·  Thomas Newton, MD (1)

Results publications

PMID 22775772, PMID 42423707, PMID 16887281, PMID 17084789, PMID 17523584, PMID 17624688, PMID 17907858, PMID 17931826, PMID 18068905, PMID 21190403, PMID 22319592, PMID 22695473, PMID 24577287, PMID 25982006, PMID 26239766, PMID 27658192, PMID 30240978

NIH funding

P50DA018197 (2), 1RC1DA028387 (1), P50DA009236 (1), R01DA017444 (1), R01DA019078 (1), R01DA023624 (1), R01DA031000 (1), U54DA039002 (1)